Actively Recruiting

Lymphoma Clinical Trials

Find recruiting clinical trials for lymphoma in the UK — including Hodgkin lymphoma, diffuse large B-cell (DLBCL), follicular, and T-cell lymphoma subtypes. See treatment pathways and where trials fit in.

Free to use — Live data from ClinicalTrials.gov — Updated hourly

🎯 Smart Matcher — Find Trials For You

Answer a few questions about your condition and we'll match you to the most relevant clinical trials.

Find My Matches →

Lymphoma Treatment Pathway

See where clinical trials fit into your treatment journey

Hodgkin — Early

Early-stage classical Hodgkin lymphoma

Standard: ABVD chemotherapy ± radiotherapy, or AVD + Brentuximab

DLBCL — 1st Line

Diffuse large B-cell lymphoma

Standard: R-CHOP chemo-immunotherapy (6 cycles)

Relapsed / Refractory

After initial treatment failure

Standard: Salvage chemotherapy + stem cell transplant, or CAR-T therapy

Follicular

Indolent (slow-growing) lymphoma

Standard: Watch and wait, then R-CHOP or R-bendamustine, maintenance Rituximab

About Lymphoma

Hodgkin Lymphoma

Highly curable cancer of the lymphatic system. Characterised by Reed-Sternberg cells. Most common in young adults aged 20-40.

DLBCL

Diffuse large B-cell lymphoma — the most common type of non-Hodgkin lymphoma. Fast-growing but often curable with R-CHOP chemo-immunotherapy.

Follicular Lymphoma

Slow-growing (indolent) non-Hodgkin lymphoma. Often managed with "watch and wait" initially. New therapies include bispecific antibodies.

Search Lymphoma Trials

Loading trials from ClinicalTrials.gov...

Frequently Asked Questions

Bispecific antibodies (like Glofitamab, Epcoritamab) redirect your immune T-cells to attack lymphoma cells. They are showing excellent results in relapsed/refractory lymphoma and may eventually replace the need for CAR-T therapy.

Yes. Some trials specifically target patients in the watch-and-wait phase, testing whether early intervention can prevent or delay the need for chemotherapy.

CAR-T (Yescarta, Kymriah) is available on the NHS for relapsed/refractory DLBCL and some other lymphomas. Clinical trials may offer access to next-generation CAR-T or newer immunotherapies.

Yes. Newer approaches include bispecific antibodies, checkpoint inhibitors, lenalidomide-based regimens, and targeted therapies that can be used without traditional chemotherapy.

How to Join a Lymphoma Clinical Trial

1

Search

Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.

2

Discuss

Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.

3

Contact

Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.

4

Enrol

If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.

Related Comparisons

🗺️ Related Pathway: Oncology & Cancer Pathway